This is the authors' abstract. We don't add key points for this paper.
This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Haslam et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: